Information Provided By:
Fly News Breaks for September 25, 2019
ACAD
Sep 25, 2019 | 07:17 EDT
Canaccord analyst Sumant Kulkarni updated his model on Arcadia as he continues to like the DRP opportunity after the company stopped its Phase 3 trial for pimavanserin after hitting a high bar on an interim efficacy analysis. The analyst said he likes the setup heading into its next catalyst as well as the scarcity value for strategic interests in neuro indications which remain very difficult to successfully develop products in. Kulkarni reiterated his Buy rating and $50 price target on Arcadia shares.
News For ACAD From the Last 2 Days
There are no results for your query ACAD
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.